Author

Candace Clark

Institution: University of Pennsylvania

Observed institutions: Abramson Cancer Center, University of Pennsylvania, University of California, Berkeley

OpenAlex ID: A5104062985

Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets

2020 · Matt R. Paul, Tien-chi Pan, et al. · Journal of Clinical Investigation · 106

Metabolomics of Microliter Hemolymph Samples Enables an Improved Understanding of the Combined Metabolic and Transcriptional Responses ofDaphnia magnato Cadmium

2011 · Helen C. Poynton, Nadine S. Taylor, et al. · Environmental Science & Technology · 102

Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer

2017 · Kara N. Maxwell, Danielle Soucier-Ernst, et al. · Breast Cancer Research and Treatment · 26

Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer

2017 · Kara N. Maxwell, Danielle Soucier-Ernst, et al. · Breast Cancer Research and Treatment · 20

DTC-Flow: a flow cytometry-based detection platform for characterizing bone marrow disseminated tumor cells in breast cancer

2025 · Elizabeth M. Chislock, Tien-chi Pan, et al. · npj Breast Cancer · 2

Abstract PD9-10: Investigating the clinical utility of tumor mutational burden in predicting rapid progression and death in patients with metastatic breast cancer

2021 · Igor Makhlin, Amy S Clark, et al. · Cancer Research · 1

Abstract 618: Comparison of mutational spectra in metastatic tumors and cell-free DNA in breast cancer patients

2015 · Kara N. Maxwell, Danielle J. Soucier-Ernst, et al. · Cancer Research

Works count: 7

Citation count: 257

H-index: 4

I10-index: 4